96-Week Data From Gilead Sciences (Foster City, CA)'s Study 934 Comparing Viread(R) And Emtriva(R) To Combivir® Both In Combination With Sustiva(R) Published In Journal Of Acquired Immune Deficiency Syndrome

FOSTER CITY, Calif.--(BUSINESS WIRE)--Gilead Sciences, Inc. (Nasdaq:GILD) today announced the publication of 96-week data from an ongoing clinical trial, Study 934, in the Journal of Acquired Immune Deficiency Syndrome (JAIDS). This study compares a once-daily regimen of Viread® (tenofovir disoproxil fumarate), Emtriva® (emtricitabine) and Sustiva® (efavirenz) to a twice-daily regimen of Combivir® (lamivudine/zidovudine) with Sustiva once daily. The study article, “Tenofovir Disoproxil Fumarate, Emtricitabine, and Efavirenz Versus Fixed-Dose Zidovudine/Lamivudine and Efavirenz in Antiretroviral-Naïve Patients,” appears in the December 15 issue of JAIDS (Vol. 43; issue 5).